Nanobiotechnology

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. Industry Overview II-1

• A Curtain Raiser II-1
• What's The Obsession With Size? II-2
• Why Analysis at the Cellular Level is Important? II-2
• Lessons from Nature II-3
• Where Conventional Molecular Science Falls Short Nanobio Steps In II-3
• Conclusions II-3
• Dawn Breaks On Nanobiotechnology II-4
• Demystifying the Intriguing World of Nanobiotech II-4
• Nanoparticles: The Foundation of Nanobiotechnology II-5
• A Meeting Place of Medicine's Best Solutions II-5
• Challenges II-6
• Nanotechnology Boom Echoes Downstream II-7
• Honey, I Shrunk the World! II-7
• Nanotechnology & Biology Tie the Knot: "Two to Tango" II-8
• Nanobiotechnology: The Next Battlefield II-8
• The Promise of Nanobiotechnology II-9
• Biological Weaponries Against Diseases Come in Small Packages II-9
• Proffered Benefits of Nanobiotechnology II-10
• Opportunity & Beyond II-11
• Nanobiotechnology - Will it Live Up to the Expectations? II-11
• The Future of Nanobiotechnology: Shape of Things to Come II-12
• Nanobiotechnology: The Outer Limits II-12
• Futuristics: A Rumination II-12
• Nanobiotechnology In the Year 2015 II-13
• Field of Nanodiagnostics II-13
• Field of Regenerative Medicine II-13
• Field of Targeted Drug Delivery II-13

2. Market Dynamics II-14

• Short Market Sizzlers II-14
• Consolidation to Speed Up in Nano-Enabled Delivery Systems Market II-14
• Dearth of Blockbuster Drugs in Pipeline Sparks Interest in Nanobio II-15
• Demand for Novel Products Complements the Exuberant Outlook II-15
• Public & Private Investment Pep Up the Market II-15
• The Regulatory Framework Evolves with the Technology II-15
• Nanomaterials & Nanoparticles Witness Robust Activity II-15
• Quantum Dot Patents Pose Legal Tangles II-16
• Colloidal Quantum Dots Prices Poised to Scale Down in Long Run II-16
• Miniaturized Liquid Handling Becomes Progressive II-16
• Unrealistic Expectations Exert Pressure On the Market II-17
• High Material Costs Put a Spoke in the Market's Growth II-17
• Below Par Involvement from Pharma Biggies Limits Growth II-17
• Lack of De Facto Standards: A Challenge to Reckon With II-18
• Loosely Defined Safety Standards Creates a Niggling Worry II-18

3. Industry Issues, Challenges & Controversies II-19

• Embroilment Over Ethical Issues II-19
• Social Relevance II-19
• Economic Relevance II-20
• Major Challenges Confronting the Industry II-21
• Commercial Exploration: A Treacherous Voyage II-21
• Dendrimers Commercialization - An Uphill Task II-22
• High Production Costs and Development Complexity II-22
• Availability of Advanced Technology Alternatives II-22
• No Defined Framework to Judge New Product's Safety and Efficacy II-23

4. Industry Structure & Investment Patterns II-24

• Industry Structure: A Quick Primer II-24
• A Dissection of Select Segments II-24
• Nanoparticles II-24
• Nanotubes and Fullerenes II-25
• Dendrimers II-25
• A Peek Into the Regulatory Framework II-25
• United States II-26
• Europe II-26
• What's Grooming Nanobiotech into an Investment High Street? II-26
• Interest Ignited by Nanotechnology II-26
• Tracking Investment Patterns in Nanobiotechnology II-27
• Interest in Nanobiotechnology Spills Over II-27
• Patent Expiration Sends the Popularity Index Spiraling II-28
• Drawing Significant Venture Capital Funds II-28
• Table 1: Venture Capital Funding in Nanobiotechnology as Compared to Other Types of Nanotechnology: A
• Peek into Substantiating Numerics Taking the US Market as a Demonstrative Example II-28
• Swelling Government Grants II-29
• The State of Public Sector Funding II-29
• Table 2: Nanobiotechnology Market in Select Regions (2004): Percentage Breakdown of Public Sector Funding by Country - South Korea, Taiwan, China, Australia, Canada, and Others (includes corresponding Graph/Chart) II-30
• A Closer Look at Regional Nano Efforts II-30
• United States: Unraveling the Country's Edge II-30
• Europe: Hot On the Heels of the US II-31
• Germany II-31
• France II-31
• United Kingdom II-31
• Scandinavia II-32
• Table 3: European Nanobiotechnology Market (2003 & 2004): Percentage Breakdown of Public Sector Funding by Leading Region/Country - European Commission, Germany, France, UK, and Others (includes corresponding Graph/Chart) II-32
• Japan: A Noteworthy Region II-32

5. Nanobio's Epochal Strides In Modern Medicine II-33

• A Primer II-33
• Impact on Drug Delivery Systems II-33
• Benefits Offered II-34
• Drug Encapsulation II-34
• High Level of Specificity II-35
• Increase in Drug Solubility and Uptake II-35
• Greater Usage Flexibility II-35
• Impact On Molecular Diagnostic Imaging II-35
• Seeing The Unseen II-36
• Impact On Pharmaceutical Drug Formulations II-36
• Impact On Therapeutics II-37
• Silver Nanoparticles as Effective Antimicrobial Agents II-37
• Modern Day Nanomedicine: A Current Scenario II-38
• Nanomedicine: The Cynosure of All Eyes II-38
• Drug Delivery Systems Epitomized by Nanomedicine II-39
• Targeted NanoDrug Delivery & Release II-40
• A Peek Into Potential Nanobio Enabled Drug Carriers II-41
• Micelles II-41
• Liposomes II-41
• Dendrimers & Liquid Crystals II-41
• Nanoparticles II-41
• Polymeric Nanoparticles II-42
• Hydrogels II-42
• Molecularly Imprinted Polymers II-42
• Microelectromechanical Systems (MEMS) II-42
• Nanosuspensions II-42
• Fullerenes: A Platform for GenX Drug Delivery II-43
• Types of Nano-Based Drug Delivery Systems, Related Materials, and Structures II-43
• Dynamics of Regenerative Medicine II-44
• Tissue Engineering and Restorations II-45
• Nanotechnology Enabled Diagnostics II-45
• Promised Path Breaking Applications in Molecular Diagnostics & Imaging II-46
• In-Vitro Diagnostics II-47
• In-Vivo Diagnostics II-47
• Nanoprobes & Implantable Devices in In-vivo Imaging II-48
• Nanocomposites in Molecular Labeling & Diagnostics II-48
• Laboratory-on-a-Chip - A Revolutionary Technology in Biomolecular Detection II-49
• Biosensors - Heralding New Opportunities in Molecular Diagnostics II-49
• Despite Huge Potential ... Key Hurdles Remain in Commercialization II-50
• Magnetic Nanoparticles for Imaging Applications in MRI II-50
• Dendrimers Promise Milestone Applications in MRI II-50
• Conclusions II-51
• Gauging the Real World Impact of Nanobiotech On Cancer: A Case Study II-51
• Quantum Dots Cock a Snook at Traditional Anti-Body Labeling Agents II-52
• Chemotherapeutic Reengineering & Gene Therapy: New Treatment Regimes II-52
• Laboratory-on-chip (LOC): A Platform for Cancer Diagnosis II-53

6. Technology Overview II-54

• Nanotechnology: An Introduction II-54
• A Revolution in the Making II-54
• Nanobiotechnology: An Exposition II-55
• Nanobiotechnology & Medicine II-55
• Nanobiotechnology & Biofuels II-55
• Global Nanobiotechnology Market (2005): Major Products II-56
• Global Nanobiotechnology Market (2005): Major Products Under Development II-56
• Analysis of Major Technology Segments II-57
• Nanomaterials II-57
• Nanoparticles II-57
• Nanoparticles in Labeling or Bio Tagging II-58
• Nanoparticles as Biomarkers II-58
• Classification of Nanoparticles II-58
• Solid Nanoparticles II-58
• Solid Lipid Nanoparticles II-59
• Calcium Phosphate Nanoparticles II-59
• Dendrimers II-59
• Dendrimers as Templates for Synthesis of Hybrid Nanostructures II-59
• Nanocomposites II-60
• Lamellar Nanocomposites II-60
• Nanostructured Materials and Membranes II-60
• Nanotubes and Fullerenes II-61
• Other Nanomaterials II-61
• Nanoshells II-61
• Nanohorns II-61
• Nanocapsules II-61
• Nanodevices II-62
• Nanotools II-62
• Select Nanotools II-62
• Atomic Force Microscopes II-62
• Hot Embossing Lithography II-63
• Dip-Pen Nanolithography II-63

7. Global Research Centers and Institutions II-64

• Centre for Biologic Nanotechnology (USA) II-64
• Centre for Biological and Environmental Nanotechnology (USA) II-64
• Institute of Bioengineering and Nanotechnology (Singapore) II-64
• The Nanobiotechnology Center (USA) II-65
• The Tyndall National Institute (Ireland) II-65

8. Research & Technology Effervescence II-66

• Dendritic NanoTechnologies Develops Novel Priostar�EDendrimer Technology II-66
• Scientists Develop Novel DNA Buckyballs for Drug Delivery Applications II-66
• Nanotechnology Creates Hopes for Artificial Kidneys II-66
• Chinese Scientists Develop Novel Drug Delivery System II-66
• Scientists Attach Nanograins to Iron Oxide Nanoparticles for Drug Delivery II-67
• Researchers Employ Nanotubules to Diffuse Cancer Cells II-67
• Scientists Develop Innovative Nanoparticles for Cancer Treatment II-67
• Nanobiotech Companies Close in on Developing Avian Flu Vaccine II-68
• Silver Nanoparticles Show Promise Against HIV-1 Virus II-68
• Nanoparticles Prove Highly Active Against Water Contaminants II-68
• Nanobiotechnology Offers Major Breakthrough in New HIV Drug Development II-68
• Scientists Develop Innovative Nanoparticles to Treat Tumors II-69
• Nano-sized Polymers Offer Key Application in Treating Tumor Cells II-69
• Carbon Nanotubes Hold Promise in Development of Synthetic Muscular Tissues II-69
• Silicon Nanowires Offer Key Solutions to Cancer Detection and Diagnosis II-70
• Antigen Loaded Nanospheres Induce Immune Response II-70
• Triton's Nanotechnology Promises Potential Tool against Tumors II-70
• Carbon Nanotubes for Development of Advanced Biosensors II-71
• Scientists Develop New Technology to Produce Gold and Silver Nanoparticles II-71
• Scientists Develop Optical Biosensors from Single-Walled Carbon Nanotubes II-71
• Layer-by-Layer Nanoassembly Method for Nanocapsule Synthesis Gets Underway II-71
• Nanowires Prove Effective in Viruses Detection II-71
• Nanobiotechnology Enables SARS Test Development II-72

9. Product Introductions/Developments II-73

• Evident Technologies Introduces Metal Quantum Dot Reagents II-73
• Abraxis Oncology Launches Novel Abraxane Drug Delivery System II-73
• Nanophase Introduces Novel Zinc Oxide Nanomaterial II-73
• ANP Technologies Develops Innovative Biological Detection System II-73
• Acrongenomics Introduces Innovative Cancer Detection Equipment II-74

10. Recent Industry Activity II-75

• Invitrogen Acquires Quantum Dot Corporation II-75
• NABsys and Brown University Forge Partnership II-75
• University of Maryland Forges Partnership with University of Maryland Biotechnology Institute II-75
• ANP Technologies Partners with Cogent Systems II-75
• NCI forms Strategic Partnership with NSF II-75
• Debiopharm and Nanocarrier Ink Pact to Develop Platinum Anti Cancer Product II-76
• Capsulution and Ebara Sign Manufacturing Agreement for Nano-capsules II-76
• Invitrogen Licenses Nanoclusters Technology from Georgia Tech Research II-76
• Dendritic NanoTechnologies, Starpharma, and Dow Ink Pact II-76
• Dendritic Nanotechnologies Inks Collaboration Pact with NCL II-76
• Flamel Terminates Licensing Agreement with Biovail II-77
• MFIC Corporation and University of Massachusetts Sign Collaboration Pact II-77
• TAP Delivers Notice to Terminate Licensing Agreement with Flamel II-77
• Nanophase Inks Pact with Competitive Technologies II-77
• Infectech Changes Name to Nanologix II-77
• Arrowhead Establishes Nanobiotechnology Company II-78
• NCI Grants Funds to Establish Centers of Cancer Nanotechnology Excellence II-78
• Capsulution Bags Patents to Develop and Market Nano and Microstructures II-78
• Capsulution Receives Patent for Production of Novel Nano and Micro-Capsules II-78
• Carbon Nanotechnologies Wins 30 Patents for Small-diameter Carbon Nanotubes II-79
• Adnavance Technologies Receives Funding for M-DNA Technology II-79
• Angstrom Medica Wins FDA Approval for Nanoss�EBone Void Filler II-79
• Carbon Nanotechnologies and C Sixty Merge II-79
• Capsulution and Nanosolutions to Join Forces II-79
• UK Institutions Forge Partnership to Develop Novel Therapy for Cancer II-80
• Triton and XOMA Sign Licensing Agreement II-80
• BioTrove Receives $11.1Million Funding to Develop Nanobiotechnology Products II-80
• Alnis Secures $2.71 Million Funding from NCI II-80
• Invitrogen Acquires Genicon's RLS Technology II-80
• C Sixty Inks License, Option and Supply Agreement with Merck. II-81
• Alnis Wins Health Contract Award from NCI II-81

11. Focus on Select Global Players II-82

• Alnis Biosciences, Inc. (USA) II-82
• American Pharmaceutical Partners, Inc. (USA) II-82
• Biosante Phosphate Pharmaceuticals, Inc. (USA) II-82
• Capsulution NanoScience AG (Germany) II-82
• Carbon Nanotechnologies, Inc. (USA) II-83
• C Sixty, Inc. (USA) II-83
• Dendritic Nanotechnologies, Inc. (USA) II-83
• Dendritech, Inc. (USA) II-83
• Elan Pharmaceuticals (USA) II-84
• Flamel Technologies, Inc. (France) II-84
• iMedd, Inc. (USA) II-84
• Nanospectra Biosciences, Inc. (USA) II-84
• Nanophase Technologies Corporation (USA) II-84
• Nano-C, Inc. (USA) II-85
• Nanocyl SA (Belgium) II-85
• Nanolab Systems Ltd. (Finland) II-85
• Nanosphere, Inc. (USA) II-85
• Nanotherapeutics, Inc. (USA) II-86
• Nanosys, Inc. (USA) II-86
• PSiVida Ltd (Australia) II-86
• Quantum Dot Corp. (USA) II-86
• Starpharma Holdings Ltd. (Australia) II-87
• Sigma Aldrich Company (USA) II-87
• Triton Biosystems, Inc (USA) II-87

12. Global Market Perspective II-88

• Table 4: World Recent Past, Current & Future Analysis for Nanobiotechnology by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-88
• Table 5: World 10-Year Perspective for Nanobiotechnology by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-88
• Table 6: World Recent Past, Current & Future Analysis for Nanomaterials by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-89
• Table 7: World 10-Year Perspective for Nanomaterials by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-89
• Table 8: World Recent Past, Current & Future Analysis for Solid Inorganic Nanoparticles by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010(includes corresponding Graph/Chart) II-90
• Table 9: World 10-Year Perspective for Solid Inorganic Nanoparticles by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-90
• Table 10: World Recent Past, Current & Future Analysis for Nanocomposites by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-91
• Table 11: World 10-Year Perspective for Nanocomposites by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-91
• Table 12: World Recent Past, Current & Future Analysis for Nanostructured Materials & Membranes by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-92
• Table 13: World 10-Year Perspective for Nanostructured Materials & Membranes by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-92
• Table 14: World Recent Past, Current & Future Analysis for Nanotubes and Fullerenes by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-93
• Table 15: World 10-Year Perspective for Nanotubes and Fullerenes by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-93
• Table 16: World Recent Past, Current & Future Analysis for Other Nanomaterials by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-94
• Table 17: World 10-Year Perspective for Other Nanomaterials by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-94
• Table 18: World Recent Past, Current & Future Analysis for Nanodevices/Tools by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-95
• Table 19: World 10-Year Perspective for Nanodevices/Tools by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) II-95

III. MARKET

1. The United States III-1

• A. Market Analysis III-1
• Outlook III-1
• Industry Overview III-1
• Public Sector Funding III-1
• Major Nanobiotechnology Institutions and Centers III-2
• The Nanobiotechnology Center (NBTC) III-2
• Principal NBTC Partners III-3
• Centre for Biologic Nanotechnology (CBN) III-3
• Centre for Biological and Environmental Nanotechnology (CBEN) III-3
• Regulatory Environment III-4
• Technological Developments III-4
• Product Introductions/Developments III-7
• Strategic Corporate Developments III-8
• Key Players III-12
• B. Market Analytics III-17
• Table 20: US Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-17
• Table 21: US 10-Year Perspective for Nanobiotechnology by Technology Segment -Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) III-18

2. Japan III-19

• A. Market Analysis III-19
• Outlook III-19
• Public Sector Funding III-19
• Technological Development III-19
• B. Market Analytics III-20
• Table 22: Japanese Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-20
• Table 23: Japanese 10-Year Perspective for Nanobiotechnology by Technology Segment - Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/ Tools for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) III-21

3. Europe III-22

• A. Market Analysis III-22
• Outlook III-22
• Market Overview III-22
• European Union Banks Heavily on
• Nanobiotechnology III-22
• Nano2Life Network III-23 Major Nanobiotechnology Networks in Europe III-24
• Public Sector Funding III-24
• Table 24: European Nanobiotechnology Market (2003 & 2004): Percentage Breakdown of Public Sector Funding by Leading Region/Country -European Commission, Germany, France, UK, and Others (includes corresponding Graph/Chart) III-25
• Regulatory Environment III-25
• Registration for Novel Nanobiotech Drugs Pose Major Bottlenecks III-25
• Focus on Select Markets III-26
• Germany III-26
• France III-26
• United Kingdom III-26
• Rest of Europe III-27
• Ireland III-27
• Market Overview III-27
• Key Research Institutions/Centers in Nanobiotechnology III-28
• The Tyndall National Institute III-28
• The Centre for Research on Adaptive Nanostructures and NanoDevices III-28
• The National Centre for Sensor Research III-28
• The Sami Nasr Institute for Advanced Materials Science III-28
• Technological Developments III-29
• Strategic Corporate Developments III-29
• Key Players III-31
• B. Market Analytics III-33
• Table 25: European Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-33
• Table 26: European 10-Year Perspective for Nanobiotechnology by Technology Segment - Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/ Tools for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart) III-34

4. Rest of World III-35

• A. Market Analysis III-35
• Outlook III-35
• Public Sector Funding III-35
• Table 27: Nanobiotechnology Market in Rest of World (2004): Percentage Breakdown of Public Sector Funding by Leading Country - South Korea, Taiwan, China, Australia, Canada, and Others (includes corresponding Graph/Chart) III-36
• Focus on Select Markets III-36
• Australia III-36
• Market Overview III-36
• Innovative Drug Delivery - A Key Focus Area for Major Australian Companies III-36
• Nanobiotechnology Offers Major Breakthrough in HIV Drug Development III-37
• Major Institution III-37
• India III-38
• Market Overview III-38
• Korea III-38
• Market Overview III-38
• Table 28: Korean Nanobiotechnology Market (2003 & 2004): Funding in US$ Million by Major Organization Type - University Centers, Public Research Institution, and Companies (includes corresponding Graph/Chart) III-39
• Key Players III-39
• B. Market Analytics III-40
• Table 29: Rest of World Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-40
• Table 30: Rest of World 10-Year Perspective for Nanobiotechnology by Technology Segment - Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools for Years 2000, 2005 & 2010. (includes corresponding Graph/Chart) III-41

IV. COMPETITION

• 1. Abraxis Bioscience, Inc. (USA) IV-1
• Table 31: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-2
• Table 32: First Quarter Sales Analysis by Product: 2005-2006 (Q1) (In US$ million) IV-2
• Table 33: Annual Sales Analysis: 2003-2005 (In US$ million) IV-2
• Abraxis Oncology (USA) IV-2
• 2. Acrongenomics, Inc. (Canada) IV-3
• 3. Ademtech SA (France) IV-4
• 4. Adnavance Technologies, Inc. (Canada) IV-5
• 5. Advanced Micro/Nano Devices Lab (Canada) IV-6
• 6. Advion Biosciences, Inc. (USA) IV-7
• 7. Albany Molecular Research, Inc. (USA) IV-8
• Table 34: Annual Sales Analysis: 2003-2005 (In US$ million) IV-8
• 8. Alnis Biosciences, Inc. (USA) IV-11
• 9. Ambri Limited (Australia) IV-12
• Table 35: Half Yearly Sales Analysis: 2005-2006 (H1) (In A$ million) IV-13
• Table 36: Annual Sales Analysis: 2004-2005 (In A$ million) IV-13
• Table 37: Annual Sales Analysis: 2003-2004 (In A$ million) IV-13
• 10. Angstrom Medica, Inc. (USA) IV-14
• 11. ANP Technologies, Inc. (USA) IV-15
• 12. Arrowhead Research Corporation (USA) IV-16
• Calando Pharmaceuticals, Inc. (USA) IV-16
• 13. Asklepios Biopharmaceutical, Inc. (USA) IV-17
• 14. BioDelivery Sciences International (USA) IV-18
• Table 38: Annual Sales Analysis: 2004-2005 (In US$ million) IV-18
• 15. BioForce Nanosciences, Inc. (USA) IV-20
• 16. BioNano International Singapore Pte., Ltd. (Singapore) IV-21
• 17. Biophage Pharma, Inc. (Canada) IV-22
• 18. Biosante Pharmaceuticals, Inc. (USA) IV-24
• Table 39: Annual Sales Analysis: 2003-2005 (In US$ thousand) IV-24
• Table 40: Annual Sales Analysis by Quarter: 2004-2005 (In US$ thousand) IV-25
• 19. Biotrove, Inc. (USA) IV-26
• 20. Biovail Corporation (Canada) IV-28
• Table 41: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-29
• Table 42: Annual Sales Analysis: 2003-2005 (In US$ million) IV-30
• Table 43: Annual Sales Analysis by Operation: 2004-2005 (In US$ million) IV-30
• Table 44: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-30
• Table 45: Annual Sales Analysis by Operation: 2003-2004 (In US$ million) IV-30
• Table 46: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-30
• 21. Capsulution Nanoscience AG (Germany) IV-35
• 22. Carbon Nanotechnologies, Inc. (USA) IV-37
• C Sixty, Inc. (USA) IV-39
• 23. Cogent Systems, Inc. (USA) IV-40
• Table 47: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-40
• Table 48: First Quarter Sales Analysis by Geographic Region: 2005-2006 (Q1) (In US$ million) IV-41
• Table 49: Annual Sales Analysis: 2003-2005 (In US$ million) IV-41
• Table 50: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-41
• Table 51: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-41
• 24. Competitive Technologies, Inc. (USA) IV-45
• Table 52: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million) IV-45
• Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million) IV-46
• Table 53: Annual Sales Analysis: 2003-2005 (In US$ million) IV-46
• Table 54: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-46
• Table 55: Quarterly Sales Analysis: 2003-2004 (In US$ million) IV-46
• 25. Concentris GmbH (Switzerland) IV-48
• 26. Crystalplex Corporation (USA) IV-50
• 27. CytImmune Science, Inc. (USA) IV-51
• 28. Cytoplex Biosciences (USA) IV-52
• 29. Debiopharm SA (Switzerland) IV-53
• 30. Dendritech, Inc. (USA) IV-55
• 31. Dendritic Nanotechnologies, Inc. (USA) IV-56
• 32. Do-Coop Technologies Ltd. (Israel) IV-57
• 33. Dow Nanotechnology (USA) IV-58
• 34. Ebara Corporation (Japan) IV-59
• Table 56: Annual Sales Analysis: 2003-2005 (In ¥ billion) IV-61
• Table 57: Annual Sales Analysis by Segment: 2004-2005 (In ¥ billion) IV-61
• Table 58: Annual Sales Analysis by Geographic Region: 2004-2005 (In ¥ billion) IV-61
• Table 59: Annual Sales Analysis by Segment: 2003-2004 (In ¥ billion) IV-61
• Table 60: Annual Sales Analysis by Geographic Region: 2003-2004 (In ¥ billion) IV-61
• 35. Eiffel Technologies Ltd. (Australia) IV-63
• Table 61: Annual Sales Analysis: 2003-2005 (In US$ million) IV-63
• 36. Elan Corporation PLC (Ireland) IV-65
• Table 62: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-66
• Table 63: Annual Sales Analysis: 2003-2005 (In US$ million) IV-66
• Table 64: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-66
• Table 65: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-67
• Table 66: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-67
• Table 67: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-67
• Elan Pharmaceuticals (USA) IV-69
• 37. Evident Technologies (USA) IV-70
• 38. Exqor (USA) IV-71
• 39. Flamel Technologies SA (France) IV-72
• Table 68: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-73
• Table 69: Annual Sales Analysis: 2003-2005 (In US$ million) IV-73
• Table 70: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-73
• Table 71: Annual Sales Analysis by Quarter: 2003-2004 (In US$ million) IV-73
• 40. Fluidigm Corporation (USA) IV-76
• 41. Genefluidics, Inc. (USA) IV-78
• 42. Genencor International, Inc. (USA) IV-79
• Table 72: Annual Sales Analysis: 2003-2004 (In US$ million) IV-80
• Table 73: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-80
• Table 74: Quarterly Sales Analysis: 2003-2004 (In US$ million) IV-80
• 43. Georgia Tech Research Corporation (USA) IV-86
• 44. Imedd, Inc. (USA) IV-86
• 45. Integrated Nano-Technologies (USA) IV-87
• 46. Interdisciplinary Research Collaboration In Bionanotechnology (IRC) (UK) IV-88
• 47. Invitrogen Corporation (USA) IV-89
• Table 75: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-90
• Table 76: Annual Sales Analysis: 2003-2005 (In US$ million) IV-90
• Table 77: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million) IV-90
• 48. JPK Instruments AG (Germany) IV-96
• 49. Kereos, Inc. (USA) IV-98
• 50. Luna Innovations, Inc. (USA) IV-100
• 51. MagnaMedics GmbH IV-103
• 52. Merck & Co., Inc. (USA) IV-105
• Table 78: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-106
• Table 79: First Quarter Sales Analysis by Product: 2005-2006 (Q1)
• (In US$ million) IV-106
• Table 80: Annual Sales Analysis: 2003-2005 (In US$ million) IV-106
• Table 81: Annual Sales Analysis by Product: 2004-2005 (In US$ million) IV-107
• Table 82: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-107
• Table 83: Annual Sales Analysis by Product: 2003-2004 (In US$ million) IV-107
• Table 84: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-108
• 53. MFIC Corporation (USA) IV-112
• Table 85: Annual Sales Analysis: 2003-2005 (In US$ million) IV-112
• Table 86: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-113
• Table 87: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-113
• Table 88: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-113
• Table 89: Quarterly Sales Analysis: 2003-2004 (In US$ million) IV-113
• 54. Nabsys, Inc. (USA) IV-115
• 55. Nacbo (Italy) IV-115
• 56. Nano Interface Technology, Inc. (NITI) (USA) IV-116
• 57. NanoBioMagnetics, Inc. (USA) IV-116
• 58. NanoBioNexus (USA) IV-117
• 59. Nanobiosym, Inc. (USA) IV-118
• 60. Nano-C, Inc. (USA) IV-118
• 61. NanoCarrier Co., Ltd. (Japan) IV-119
• 62. Nanocyl SA (Belgium) IV-120
• 63. Nanodisc, Inc. (USA) IV-121
• 64. Nanodynamics, Inc. (USA) IV-122
• 65. NanoLab, Inc. (USA) IV-126
• 66. Nanolab Systems Ltd. (Finland) IV-126
• 67. Nanolight Technologies (USA) IV-127
• 68. Nanologix, Inc. (USA) IV-128
• 69. NanoNord A/S (Denmark) IV-129
• 70. Nanophase Technologies Corporation (USA) IV-130
• Table 90: First Quarter Sales Analysis: 2005-2006 (Three Months Ended, March) (In US$ millions) IV-130
• Table 91: First Quarter Sales Analysis By Operations: 2005-2006 (Three Months Ended, March) (In US$ millions) IV-131
• Table 92: Annual Sales Analysis: 2003-2005 (In US$ millions) IV-131
• Table 93: Annual Sales Analysis By Operations: 2004-2005 (In US$ millions) IV-131
• Table 94: Annual Sales Analysis By Operations: 2003-2004 (In US$ millions) IV-131
• Table 95: Quarterly Sales Analysis: 2004-2005 (In US$ millions) IV-131
• Table 96: Quarterly Sales Analysis: 2003-2004 (In US$ millions) IV-132
• 71. Nanoplex Technologies, Inc. (USA) IV-135
• 72. Nanoprobes, Inc. (USA) IV-136
• 73. Nanosolutions GmbH (Germany) IV-137
• 74. Nanospectra Biosciences, Inc. (USA) IV-137
• 75. Nanosphere, Inc. (USA) IV-138
• 76. Nanosys, Inc. (USA) IV-139
• 77. Nanotherapeutics, Inc. (USA) IV-142
• 78. Nanoxis AB (Sweden) IV-143
• 79. National Physical Laboratory (UK) IV-144
• 80. Platypus Technologies, LLC (USA) IV-146
• 81. Proteinx Lab (USA) IV-147
• 82. PSiVida Ltd. (Australia) IV-148
• 83. Sigma-Aldrich Corporation (USA) IV-149
• Table 97: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million) IV-150
• Table 98: Annual Sales Analysis: 2003-2005 (In US$ million) IV-150
• Table 99: Quarterly Sales Analysis: 2004-2005 (In US$ million) IV-150
• Table 100: Annual Sales Analysis by Segment: 2004-2005 (In US$ million) IV-150
• Table 101: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million) IV-151
• Table 102: Quarterly Sales Analysis: 2003-2004 (In US$ million) IV-151
• Table 103: Annual Sales Analysis by Segment: 2003-2004 (In US$ million) IV-151
• Table 104: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million) IV-151
• 84. SRU Biosystems, Inc. (USA) IV-158
• 85. Starpharma Holdings Limited (Australia) IV-159
• Table 105: Half Yearly Sales Analysis: 2005-2006 (H1) (In A$ million) IV-159
• Table 106: Annual Sales Analysis: 2003-2005 (In A$ million) IV-160
• Table 107: Annual Sales Analysis by Segment: 2004-2005 (In A$ million) IV-160
• Table 108: Annual Sales Analysis by Segment: 2003-2004 (In A$ million) IV-160
• 86. Tap Pharmaceutical Products, Inc. (USA) IV-162
• 87. Triton Biosystems, Inc. (USA) IV-163
• 88. U.S. Genomics, Inc. (USA) IV-164
• 89. Visigen Biotechnologies, Inc. (USA) IV-168
• 90. Vulvox Nano/Biotechnology Corporation (USA) IV-169
• 91. Xoma Ltd. (USA) IV-170
• Table 109: Annual Sales Analysis: 2004-2005 (In US$ thousand) IV-170
• Table 110: Annual Sales Analysis by Segment: 2004-2005 (In US$ thousand) IV-170
• Table 111: Annual Sales Analysis by Geographical Region: 2004-2005 (In US$ thousand) IV-170